Monitor upcoming quarterly filings for actual biosimilar sales traction and any updates on the pipeline of additional products expected in 2027. The long-term revenue projections ($20-25M by 2030) are modest relative to Kamada's existing plasma-derived product revenue, so near-term stock impact likely limited.
Price Chart
Executive Summary
Kamada announced the commercial launch of two new biosimilar products in Israel: Ustekinumab-Kamada (biosimilar to Stelara) and Enoxaparin-Kamada (biosimilar to Clexane), expanding its biosimilar portfolio to four marketed products. The company expects its existing biosimilar portfolio to generate approximately $4 million in sales in 2026, growing to approximately $10 million in 2028, and $20-25 million annually by 2030. This is a strategic expansion of a growth pillar, but the revenue projections are forward-looking and the current contribution is small relative to the company's overall business.
Key Facts
- Kamada launched two new biosimilars in Israel: Ustekinumab-Kamada (Stelara biosimilar) and Enoxaparin-Kamada (Clexane biosimilar).
- This brings the total marketed biosimilar portfolio to four products, adding to Bevacizumab-Kamada and Pegfilgrastim-Kamada.
- Existing biosimilar portfolio expected to generate ~$4 million in sales in 2026, ~$10 million in 2028, and ~$20-25 million annually by 2030.
- Company expects at least two additional biosimilar products to be commercially available during 2027.
- By 2030, Kamada expects the portfolio to include at least 12 marketed products from 6 licensing partners in Israel and MENA region.
Financial Impact
Biosimilar portfolio expected to generate ~$4M in 2026, ~$10M in 2028, and ~$20-25M annually by 2030. These are forward-looking projections, not current revenue.
Risk Factors
- Forward-looking revenue projections may not materialize due to competitive dynamics, pricing pressure, or regulatory delays.
- Geopolitical risks in Israel and MENA region could disrupt commercialization.
- Biosimilar market entry faces competition from other manufacturers and potential reference product price erosion.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-106968 |
| Document: ea0307676-6k_kamada.htm | 0001213900-26-106968 |
| Document: 0001213900-26-106968-index-headers.html | 0001213900-26-106968 |
| Document: 0001213900-26-106968-index.html | 0001213900-26-106968 |
| Document: 0001213900-26-106968.txt | 0001213900-26-106968 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $8.11 | awaiting T+20 | — | $8.05 (−0.74%) |
Oct 6, 2026 21d ago | Press Release | $8.11 | awaiting T+20 | — | $8.05 (−0.74%) |
Oct 5, 2026 22d ago | 6-K | $8.11 | awaiting T+20 | — | $8.05 (−0.74%) |
Sep 17, 2026 5w ago | 6-K | $8.67 $7.83 | ▼ −9.69% | ▼ −10.89% | $8.05 (−7.15%) |
Sep 16, 2026 6w ago | EFFECT | $8.19 $7.69 | ▼ −6.11% | ▼ −9.28% | $8.05 (−1.71%) |
Sep 10, 2026 6w ago | 6-K | $7.99 $7.78 | ▼ −2.69% | ▼ −4.82% | $8.05 (+0.75%) |
Sep 3, 2026 7w ago | Press Release | $8.54 $8.00 | ▼ −6.32% | ▼ −6.93% | $8.05 (−5.74%) |
Sep 3, 2026 7w ago | 6-K | $8.54 $8.00 | ▼ −6.32% | ▼ −6.93% | $8.05 (−5.74%) |
Aug 17, 2026 10w ago | 6-K / PRESS-RELEASE | $7.76 $8.09 | ▲ +4.25% | ▲ +6.23% | $8.05 (+3.74%) |
Aug 12, 2026 10w ago | 6-K | $6.88 $7.99 | ▲ +16.13% | ▲ +18.03% | $8.05 (+17.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers